Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Enzene’s New Jersey facility offers efficient, fully continuous or hybrid vat production within a modular framework.

I have always been a bit of a skeptic about how important AI will be for the biotechnology industry, but, given a few […] ...

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.